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Summary
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized 
by isolated thrombocytopenia (< 100 x109/L) in the absence of known causes. It is characterized 
by mucocutaneous bleeding and has a chronic and unpredictable course. Diagnosis of ITP is 
based on exclusion criteria. Its pathogenesis involves both increased destruction of platelets op-
sonized by antiplatelet autoantibodies and impaired platelet production. The majority of patients 
with ITP are either asymptomatic or have mild to moderate bleeding, while only the few with 
severe symptoms undergo treatment of unpredictable duration and effectiveness. Not until 2009 
was the international consensus report on terminology, definitions and outcome criteria provi-
ded for ITP. Factors to be considered during treatment include bleeding, comorbidities, activity 
and lifestyle, individual tolerance of side effects, patient preferences and concerns, and finally 
the platelet count. The overall mortality rate of 1-5% and morbidity may be attributed equally to 
bleeding and to treatment-related infections. While there is general agreement about treatment 
of newly presenting adults with ITP, few evidence-based studies direct therapies in relapsed and 
refractory patients. Thrombopoietin receptor agonist targeting impaired platelet production re-
presents a revolution in the treatment of refractory ITP. 
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INTRODUCTION
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder 
characterized by isolated thrombocytopenia (< 100 x109/L) in the absence of condi-
tions known to cause thrombocytopenia. It is characterized by skin and mucosal 
bleeding and has a chronic and unpredictable course. In the absence of a "gold-stan-
dard" test, diagnosis of ITP is based on exclusion criteria [1,2].
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Terminology, classification, definitions and demographics
It was not until 2009 that the International Working Group (IWG) on ITP pro-
vided a consensus report on terminology, definitions and outcome criteria for this 
disease [1]. A new staging scheme was also proposed by the IWG, defining the 
following stages of ITP: ‘newly diagnosed‘ (diagnosis to 3 months), ‘persistent‘ (4-
12 months) and ‘chronic‘(≥ 12 months duration). The term ‘severe ITP‘ stands for 
patients with major bleeding, while ‘refractory ITP‘ is defined as severe ITP after 
splenectomy. ITP is a relatively rare disorder in adults with an estimated incidence 
of 1-4/100.000 persons. Historically, it is typically seen in women in the reproducti-
ve period. However, recent epidemiologic data showed that the incidence increases 
with age with the maximal age-specific incidence in the 8th and 9th decades. The 
median age at diagnosis is 56 years. Prevalence in elderly female patients ≥ 65 years 
old and males of a similar age was equal [3,4].
Pathophysiology 
The mechanisms of thrombocytopenia in ITP involve both increased platelet de-
struction and impaired platelet production. The emergence of antiplatelet autoantibo-
dies remains the central pathogenic mechanism. These antibodies are directed aga-
inst a restricted number of dominant epitopes on glycoproteins (GP) IIb/IIIa and Ib/IX. 
Autoantibodies opsonize platelets, which are taken up and destroyed by macropha-
ges predominantly in the spleen. They also bind to bone marrow megakaryocytes, 
thereby impairing megakaryocyte maturation and platelet production [5,6]. T-cells 
are also involved in the pathogenetic process in ITP. Namely, expansion of oligoclo-
nal T-cells together with platelet- and megakaryocyte- reactive cytotoxic T-cells and 
suppressed regulatory T-cells have been identified in ITP patients. The emergence of 
antiplatelet autoantibodies and antiplatelet cytotoxic T-cells is a consequence of loss 
of immunological tolerance for self antigens. In some patients response to Helicobacter 
pylori and hepatitis B and C infection may generate antibodies that cross-react with 
platelet antigens. In addition, genetic factors might contribute to the predisposition 
to develop ITP or influence the natural history of ITP and treatment response. Such a 
complex pathophysiology of ITP explains its clinical heterogeneity [6].
Signs and symptoms 
The majority of ITP patients are either asymptomatic or with mild to moderate 
bleeding, typically mucocutaneous. The intensity of bleeding correlates with the se-
verity of thrombocytopenia and the patients' age, with the highest rate of severe or 
fatal hemorrhage in patients > 60 years old and those with platelet counts < 10 x109/l 
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[7,8]. Addressing this issue the IWG proposed that bleeding symptoms should be 
measured by a validated scale and expressed in bleeding scores [1,9]. Spontaneous 
remission is a rare phenomenon occurring in less than 10% of patients. Moreover, 
only a minority of patients exhibit severe ITP and the overall mortality rate of 1-5% 
could be attributed either to bleeding or to treatment-related infections. [7,8,10,11].
The diagnosis is based on exclusion of myriad causes of isolated thrombocyto-
penia such as: pseudothrombocytopenia, inherited thrombocytopenia, thrombo-
cytopenia in pregnancy, cyclic thrombocytopenia, drug-induced thrombocyto-
penia, infections, various bone marrow diseases, autoimmune systemic diseases, 
lymphoproliferative disorders, liver disease, common variable immune deficiency, 
posttransfusion purpura and thrombotic microangiopathy syndromes [2].
Essential investigations in ITP include: history and physical examination, com-
plete blood cell counts including reticulocytes, examination of a peripheral blood 
film, determination of immunoglobulin concentration, blood group Rh (D) typing, 
direct antiglobulin test and testing for Helicobacter pylori, and hepatitis B and C in-
fection. A bone marrow examination should be considered in patients older than 60 
years, in those with systemic symptoms and before splenectomy [2].
ITP is not considered a minor disease any longer, because the patients exhibit an 
impaired health-related quality of life (HRQoL) comparable to that observed with 
other serious chronic diseases (hemophilia, arthritis, diabetes, cancer) [12]. In addi-
tion, patients with primary ITP are at an increased risk for venous thromboembolic 
events compared to those without ITP [13]. Moreover, patients with primary ITP 
have a substantially enhanced long-term risk of infections, hemorrhagic episodes 
requiring hospitalization, hematologic malignancies and mortality [14].
Management 
In general the treatment should be tailored to the individual patient and in line 
with current guidelines [2,15]. The therapeutic goals are as follows: to provide a 
safe platelet count to prevent or stop hemorrhages, to avoid overtreatment and to 
ensure a satisfactory HRQoL. Factors to be considered include: whether the patient 
is bleeding, comorbidities, activity and lifestyle, individual tolerance of side effects, 
patient preferences and concerns, and finally the platelet count. Treatment should 
not be based solely on platelet counts, but is prescribed according to the individual 
bleeding risk. In general, treatment is initiated in patients with a platelet count < 30 
x109/L and rarely in those with higher counts (if bleeding or with risks for bleeding) 
[2,15]. In addition, activity restriction and avoidance of non steroid antirheumatic 
and intramuscular injections are advised.
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Corticosteroids at a dose of 0.5-2 mg/kg for 2-4 weeks are the standard initial 
treatment. Up to 75% of patients respond but only 10-30% of them obtain a sustai-
ned higher platelet count. The mechanisms of corticosteroid action encompass su-
ppression of macrophage function, inhibition of antibody binding to platelets and 
reduction of antibody production. Notable side effects of corticosteroids are infec-
tions, hypertension, glaucoma, cuchingoid appearance, diabetes mellitus, anxiety, 
osteoporosis and avascular necrosis of the hip. Intravenous immunoglobulin (IVIg) 
is also an effective treatment for ITP with nearly 80% responders for a period up to 
3-4 weeks after therapy initiation. IVIg is administered at a dose of 2 mg /kg but is 
usually reserved for emergency treatment. The mechanisms of IVIg action are vari-
ous: Fc receptor blockade, anti-idiotype antibodies in IVIG reaction with epitopes on 
the patients' autoantibodies. Among IVIg toxicities, headache, nausea, chills, aller-
gic manifestations are common phenomena, while aseptic meningitis, thrombosis, 
hemolytic anemia and renal failure are rare. 
Splenectomy (a second-line treatment) is an efficient therapy offering a susta-
ined response in about 65% of patients [2,16]. Splenectomy removes the major site 
of destruction of antibody-sensitized platelets and also the major place of antibody 
synthesis. ITP guidelines recommend suspension of splenectomy for at least 6 
months after diagnosis [2] due to the possibility of attaining spontaneous remission 
[2,15]. The relapse rate increases with time and 10% of relapses are due to hyper-
trophy of accessory spleens. Actually, the rate of splenectomy in primary ITP pati-
ents has dropped from 50-60% to 20-30% in the last decade due to the emergence of 
new drugs and the fact that splenectomized patients are immunocompromised for 
life. 
For the 25-35% of refractory ITP patients, treatment options are TPO-receptor 
agonists (TPO-RA) [2,15]. TPO-RA are a new class of drug, eltrombopag being a 
non-competitive and romiplostim a competitive agent. They both activate the same 
signal pathway as endogenous TPO. They have the potential to increase the platelet 
count, to decrease bleeding manifestations and to improve the HRQoL in 80% of 
ITP patients, both splenectomized and non-splenectomized. Thus the use of TPO-
receptor agonists has become the cornerstone of treatment for chronic refractory 
ITP [17, 18]. Eltrombopag is an oral non-peptide small molecule administered daily, 
while romiplostim, an Fc-peptide fusion protein (or ‘peptibody’), is administered as 
a weekly subcutaneous injection. Several extensive, randomized, placebo controlled 
long-term clinical studies using both drugs showed that there were no important 
drug toxicities. Upon cessation of treatment, most patients returned to their basal 
platelet level [2,17,18]. However, cases of durable remissions after TPO-RA disconti-
nuation in adult ITP have been reported recently [19]. 
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CONCLUSION
Although guidelines provide the treating physician with the best current evi-
dence relating to the diagnosis and management of ITP, we should remember that 
no diagnostic or treatment algorithm is suitable for all. Since guidelines always fall 
behind new research data, it is up to the physician to follow the principal medical 
literature.
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Sažetak
Primarna imunološka trombocitopenija u odraslih - suvremeni pristup
Primarna imunološka trombocitopenija (ITP) je stečena autoimuna bolest koja se odlikuje 
izoliranom trombocitopenijom nižom od 100x109/L i odsustvom svih stanja i bolesti koje mogu 
dovesti do trombocitopenije. Karakterizirana je sklonošću krvarenju po koži i sluznicama, ima 
kronični tijek a ishod bolesti je nepredvidiv. Dijagnoza ITP se postavlja isključivanjem. Etiopato-
geneza ITP je kompleksna i podrazumijeva prijevremenu razgradnju trombocita obloženih auto-
antitijelima kao i neefikasnu megakariocitopoezu. Većina bolesnika prikazuje slabo do umjereno 
izražene simptome, a samo manjina zahtjeva liječenje koje je dugotrajno i nepredvidivog ishoda. 
Tek 2009. godine provedena je standardizacija kako terminologije tako i definicija stadija bolesti 
i kriterija terapijskog odgovora kod ITP. Odluka o započinjanju liječenja se donosi na osnovu 
intenziteta i lokalizacije krvarenja, prisustva dodatnih faktora rizika za krvarenje, komorbiditeta, 
individualnog toleriranja neželjenih efekata liječenja i broja trombocita, a uvažavajući želje pa-
cijenata. Stopa smrtnosti je 1-5% i posljedica je krvarenja i infekcija nastalih tijekom liječenja. 
Za razliku od liječenja novodijagnosticirane ITP, za liječenje refraktorne ITP, zasada ne postoje 
jasne preporuke. Revoluciju u liječenju refraktorne ITP predstavljaju agonisti trombopoetinskih 
receptora koji popravljaju neefikasnu megakariocitopezu.
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